Who we are
Board of Recommendation
How to Become a Member
Members’ Activities Calendar
What we do
Policy and Advocacy
Exchange the world
Introduction to IFMSA Exchanges
List of Participating Countries
Research Projects Database
Medical Students International
You are here:
Expression of potential oncological biomarkers PLAGL2 and DDR2 in clear cell renal cell carcinoma (ccRCC): correlation with clinicopathological characteristics and overall survival of patients with ccRCC
Poland (IFMSA-Poland) - University of Warmia and Mazury in Olsztyn, Olsztyn
Department of Human Histology and Embryology School of Medicine, Collegium Medicum, University of Warmia and Mazury in Olsztyn Warszawska 30, 10-082 Olsztyn, Poland
Bartlomiej Emil Krazinski, PhD
Type of Research Project
- Basic science
What is the background of the project?
Pleiomorphic adenoma gene-like 2 (PLAGL2) is a zinc finger protein that can bind specific sequences of DNA to activate transcription of its target genes. Altered expression of PLAGL2 has been linked to the development of several human malignancies such as colon cancer, lung cancer, glioma, prostate cancer, myeloid leukemia and other tumors. PLAGL2 is considered biomarker and potential target for anticancer therapies in those tumors. Discoidin domain receptor 2 (DDR2) is a receptor tyrosine kinase that is activated by collagen in the xtracellular matrix. DDR2 mutations or alternate expression correlate with the progression of several cancers including lung and colorectal tumors. To date the expression of PLAGL2 and its significance as a putative prognostic marker in clear cell renal cell carcinoma (ccRCC) has not been studied.
What is the aim of the project?
The project aims to determine the expression levels of PLAGL2 at the mRNA and/or protein levels in the samples of ccRCC tumors, noncancerous kidney tissues and renal cancer cell lines.
What techniques and methods are used?
1. RNA extraction 2. Reverse transcription (RT) 3. Quantitative polymerase chain reaction (qPCR) a. PLAGL2 b. DDR2 4. Tissue sectioning 5. Immunochemistry a. PLAGL2 b. DDR2 6. Statistical analysis of results including survival analysis
What is the role of the student?
- The tasks will be done under supervision
What are the tasks expected to be accomplished by the student?
Student is expected to complete (working under supervision of the tutor and other scientific employees) at least four out of eight below-listed tasks: 1. Reverse transcription and quantitative polymerase chain reaction (RT-qPCR) – student will learn how to plan and set those reactions. a. PLAGL2 TaqMan assay b. DDR2 TaqMAn assay 2. Sectioning od parrafin-embedded tissue blocks using a microtome. 3. Tissue staining using standard hematoxylin-eosin procedure. 4. Immunohistochemistry (IHC-P) using speicfic anti-human antibodies: a. PLAGL2 or b. DDR2 antibodies. 5. In vitro culturing of renal cancer cell lines (optional). 6. Results analysis using GraphPAd Prism and StatSoft Statistica software. 7. Writing of research items and graphic presentation of the results.: a. short communicate and/or b. poster and or c. presentation.
Will there be any theoretical teaching provided (preliminary readings, lectures, courses, seminars etc)
Theoretical teaching will be provided by the tutor as readings (articles and manuals) and respective trainings with the special emphasis on the safety regulations and good laboratory practice.
What is expected from the student at the end of the research exchange? What will be the general outcome of the student?
- The student will prepare a poster - The student will prepare a scientific report - The student will prepare an abstract - The student will prepare a presentation
What skills are required of the student? Is there any special knowledge or a certain level of studies needed?
An ideal candidate for this project: is interested in biomedical science wants to learn more about cancer biology welcomes challenges is punctual and disciplined is reliable and responsible is a team player with good interpersonal skills has a good command of English (spoken and written) Subjects passed: Medical biology or Molecular biology (or related), Cell biology, Histology, Biochemistry, Pathology. Previous experience with work at laboratory is desirable.
Are there any legal limitations in the student’s involvement
Type of students accepted
This project accepts: - Medical students - Pre-Medical students from the American-British system - Students in biomedical fields
- 1. PLAG1; the prototype of the PLAG gene family: versatility in tumour development (review). Van Dyck F; Declercq J et al. Int J Oncol. 2007 Apr;30(4):765-74. Review.
- 2. Overexpressed PLAGL2 transcriptionally activates Wnt6 and promotes cancer development in colorectal cancer. Li N; Li D; Du Y et al. Oncol Rep. 2019 Feb;41(2):875-884
- 3. Overexpression of Pleomorphic Adenoma Gene-Like 2 Is a Novel Poor Prognostic Marker of Prostate Cancer. Guo J; Wang M; Wang Z; Liu X. PLoS One. 2016 Aug 18;11(8):e0158667
- 4. Plag1 and Plagl2 are oncogenes that induce acute myeloid leukemia in cooperation with Cbfb-MYH11.
- 5. Landrette SF; Kuo YH; Hensen K; Barjesteh van Waalwijk van Doorn-Khosrovani S; Perrat PN; Van de Ven WJ; Delwel R; Castilla LH. Blood. 2005 Apr 1;105(7):2900-7
- 6. The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications. Linehan WM; Ricketts CJ. Nat Rev Urol. 2019 Sep;16(9):539-552
- 7. PLAGL1 (ZAC1/LOT1) Expression in Clear Cell Renal Cell Carcinoma: Correlations with Disease Progression and Unfavorable Prognosis. Godlewski J; Krazinski BE; Kowalczyk AE et al. Anticancer Res. 2016 Feb;36(2):617-24.
- 8. Expression and Prognostic Significance of EP300; TP53 and BAX in Clear Cell Renal Cell Carcinoma. Godlewski J; Krazinski BE; Kowalczyk AE et al. Anticancer Res. 2017 Jun;37(6):2927-2937
- 9. Altered Expression of DDR1 in Clear Cell Renal Cell Carcinoma Correlates With miR-199a/b-5p and Patients' Outcome. Krazinski BE; Kiewisz J; Sliwinska-Jewsiewicka A et al. Cancer Genomics Proteomics. 2019 May-Jun;16(3):179-193.
- Rammal H; Saby C; Magnien K; Van- Gulick L; Garnotel R; Buache E; El Btaouri H; Jeannesson P; Morjani H. Discoidin Domain Receptors: Potential Actors and Targets in Cancer. Front Pharmacol. 2016 Mar 14;7:55. doi: 10.3389/fphar.2016.00055. eCollection 2016.
© 2015 - IFMSA.org - Developed by web agency